Markowitz Wayne 4

4 · Edwards Lifesciences Corp · Filed May 11, 2026

AI-generated summary of this filing

Updated May 12, 2026

Edwards (EW) CVP Wayne Markowitz Receives Awards, Sells 593 Shares

What Happened

Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences (EW), received equity awards on May 7, 2026 and disposed of shares in connection with tax withholding and an open-market sale. The filing shows grant/award acquisitions of 5,200 RSUs, a target 26,400 performance RSUs, and 5,200 option-type awards (all reported at $0.00 on the Form 4).
Dispositions recorded: 264 shares withheld/surrendered for taxes on 2026-05-07 at $83.20 ($21,965), 226 shares withheld on 2026-05-08 at $82.76 ($18,704), and an open-market sale of 593 shares on 2026-05-11 at $79.73 ($47,280). Combined proceeds/withholdings across those disposals ≈ $87,949.

Key Details

Transaction dates & prices:
- 2026-05-07: Award — 5,200 RSUs @ $0.00 (F1); Award — 5,200 options (derivative) @ $0.00 (F2); Performance RSU Target — 26,400 shares @ $0.00 (F3).
- 2026-05-07: 264 shares disposed for tax withholding @ $83.20 = $21,965 (code F).
- 2026-05-08: 226 shares disposed for tax withholding @ $82.76 = $18,704 (code F).
- 2026-05-11: Open-market sale of 593 shares @ $79.73 = $47,280 (code S).
Shares owned after the transactions: not specified in the provided excerpt of the filing.
Footnotes: RSUs vest in four equal annual installments beginning one year after grant (F1); options vest in four equal annual installments beginning one year after grant (F2); performance RSUs (target 26,400) vest May 7, 2029 based on performance (0%–200% of target) (F3).
Filing timeliness: Transactions dated May 7 were reported on the Form 4 filed May 11, 2026 — within the standard two-business-day reporting window.

Context

The two disposals coded "F" reflect shares surrendered to cover taxes related to the awards (tax withholding), while the "S" transaction is an open-market sale (593 shares). Tax-withholding disposals are routine after grant/vesting and do not necessarily indicate a change in sentiment.
The grants include time-based RSUs, stock-option awards, and performance-based RSUs (the latter can pay out between 0%–200% of target depending on performance).

Form 4

Period: 2026-05-07

CVP, JAPAC

Transactions

Award
Common Stock
[F1]
2026-05-07+5,200→ 22,762.871 total
Tax Payment
Common Stock
2026-05-07$83.20/sh−264$21,965→ 22,498.871 total
Tax Payment
Common Stock
2026-05-08$82.76/sh−226$18,704→ 22,272.871 total
Sale
Common Stock
2026-05-11$79.73/sh−593$47,280→ 21,679.871 total
Award
Employee Stock Option (Right to Acquire)
[F2]
2026-05-07+26,400→ 26,400 total
Exercise: $82.76From: 2027-05-07Exp: 2033-05-06→ Common Stock (26,400 underlying)
Award
Performance Rights
[F3]
2026-05-07+5,200→ 5,200 total
From: 2029-05-07→ Common Stock (5,200 underlying)

Footnotes (3)

[F1]These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
[F2]These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
[F3]Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.

Signature

Linda J. Park, Attorney-in-Fact|2026-05-08

1 file